A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignancies
dc.contributor.author | Chiorean, E. Gabriela | |
dc.contributor.author | Porter, Jennifer M. | |
dc.contributor.author | Foster, Anne E. | |
dc.contributor.author | Omari, Amal S.H. Al | |
dc.contributor.author | Yoder, Christy A. | |
dc.contributor.author | Fife, Karen L. | |
dc.contributor.author | Strother, R. Matthew | |
dc.contributor.author | Murry, Daryl J. | |
dc.contributor.author | Yu, Menggang | |
dc.contributor.author | Jones, David R. | |
dc.contributor.author | Sweeney, Christopher J. | |
dc.contributor.department | Biostatistics, School of Public Health | en_US |
dc.date.accessioned | 2020-12-16T15:19:48Z | |
dc.date.available | 2020-12-16T15:19:48Z | |
dc.date.issued | 2008-02 | |
dc.description.abstract | Purpose: This study aimed to define the maximum tolerated dose of weekly docetaxel combined with daily erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor. Experimental Design: Patients with any solid tumor received 150 mg erlotinib with escalating doses of docetaxel (20, 25, 30, and 35 mg/m2) on days 1, 8, and 15 every 28 days. The pharmacokinetics of docetaxel and erlotinib was determined on cycle 2, day 1. Erlotinib was given for a maximum of 12 cycles and docetaxel was given for up to 6 cycles. Results: Twenty-five patients (17 males and 8 females) were enrolled with a median age of 56 years (range, 34-76); Eastern Cooperative Oncology Group performance status of 0/1 was 20/5. One patient had a dose-limiting toxicity in cycle 1 at the 25 mg/m2 level (grade 3 enterocolitis). At 35 mg/m2 docetaxel dose level, 6 of 10 patients required dose reductions to 30 mg/m2 beyond cycle 1 due to neutropenia (3 patients) and mucositis, increased bilirubin, and diarrhea (1 patient each). The clearance of docetaxel and erlotinib of 61.7 and 8.16 L/h, respectively, did not seem to differ from historical controls. Responses were seen in non–small cell lung cancer, prostate cancer, and hepatobiliary cancers, including a complete response lasting 36+ months in a patient with hepatocellular carcinoma. Conclusion: Although no maximum tolerated dose was reached in cycle 1 with 35 mg/m2 docetaxel, repetitive dosing proved intolerable in a substantial number of patients; thus, the recommended phase II dose of weekly docetaxel is 30 mg/m2 when combined with 150 mg of daily erlotinib. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Chiorean, E. G., Porter, J. M., Foster, A. E., Al Omari, A. S., Yoder, C. A., Fife, K. L., ... & Sweeney, C. J. (2008). A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clinical cancer research, 14(4), 1131-1137. | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/24627 | |
dc.language.iso | en_US | en_US |
dc.publisher | American Association of Cancer Research | en_US |
dc.relation.isversionof | 10.1158/1078-0432.CCR-07-0437 | en_US |
dc.relation.journal | Clinical Cancer Research | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.source | Publisher | en_US |
dc.subject | Pharmacokinetic Trial | en_US |
dc.subject | Erlotinib | en_US |
dc.subject | Weekly Docetaxel | en_US |
dc.title | A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignancies | en_US |
dc.type | Article | en_US |